DepoMed, Inc. (NASDAQ:DEPO)
A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Pharmaceuticals are on a roll lately
Recs
Article from Zacks Biotech Guy - Jason Napodano - trying a strategy where I set 10% stops on all these and let the winners run.
Recs
DepoMed's share price has recovered substantially from the lows of 4.3 seen after the failure of Breeze 3 in October. My question is, why? After the horrendous commercial performance of newly approved pain medications in the last few years, why would the share price rise going into the launch of Gralise? The only question is, in what month will disappointing revenue numbers first surface? Meanwhile, the company has yet to announce termination of development of Gabapentin GR for hot flashes. That negative catalyst should also surface in early 2012. DepoMed should be trading closer to the most recent cash position of 154M than the current cap of 284M.
Recs
PEG, P/FCF, analyst, EPS next 5 years.
Recs
almost @ cash on hand, launch of grasile should, be easy 2 bagger over 12 months
Recs
Hurt bt abt. But graise launch 150m in cash
Recs
us pharma
Recs
Significant insider buying ahead of Serada data, and Gralise launch
Recs
DepoMed exhibits revenue growth at a low valuation.
Recs
Made a Greenblatt substitute screen in CAPS = 4/5 stars, and ranked companies by a combination of ROE and Gross Margin (Quality Ranking), and also ranked by PE (Value). Then I brought in actual Greenblatt picks. This one was the highest ranked in my CAPS list (#1), and it happened to be on Greenblatt's list as well. Gross Margin of 94.7, ROE of 85.3, and a PE of 3.9. 4 Stars.
Recs
MFI Screen
Recs
Magic Formula. Insider buying. Plenty of cash and proven ability to bring in money through partnering.
Recs
magic formula
Recs
Gralise should be able to compete with generics. ER tech should pay dividends down the road.
Recs
This company has several meds in the pipeline. One just got approval(Gralise) and the other med is about to have word on approval for another med(Sereda). It also has a few other meds in the pipeline that are a year away or so. The only thing holding this stock from going to $15 - $20 a share is its contract dispute with Abbott. When that works itself out look for a nice rise in the stock price.
Recs
DepoMed’s DM-1796 will be FDA approved by or before the end of the month.
Recs
Proven technology, great pipeline, self financing and 2 potential Billion $ products. Just hope the company doesn't get bought in the next few years.
Recs
I like the number and type of products Depomed has in the pipeline. Also the relationships they have with major Pharma. Possible takeover within two years.
Recs
On the verge
Recs
When all the bad news is out and the stock has oversold below $2.50, that's when I bought with real money and expect in 5 years to be more than a 5 bagger.
Just about perfect trade!
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 39 : 1 2 Next »